Life Science Startup Avro Delivers Drug through Skin Patches
Avro, a life sciences startup is developing skin patches to deliver drug for common flue and allergies in children and adults.
The company is focused on developing patches of skin to deliver drug in people who are susceptible to common flue and seasonal allergies. The patches function similar to the nicotine patches, which can deliver nicotine to people willing to quit smoking. It can deliver medications for variety of common disorders such as allergy medication and common flue. “The drugs are also relatively safe so it’s something we can work with without being too worried,” said Shakir Lakhani, Co-founder, Avro.
There are various manufacturers which offer transdermal drug delivery. ProSolus, Miami-based pharmaceutical company offers skin patches for delivery of generic drugs and over-the-counter products. Fremont outfit Zosano provides skin patches to deliver anti-migraine drugs. Furthermore, Viaskin is involved in developing skin patch for children who are allergic to peanut.
However, Avro is working on clearing clinical trials to prove its safety and efficacy. The company is focused on receiving FDA approval for marketing the product in the U.S. and Canada. The company reported that it is conducting human clinical trials to bring out product in market by the end of 2018. “We’re looking at things like people suffering from neurodegenerative diseases and more intense diseases that inhibit your ability to swallow, like Multiple Sclerosis,” said Lakhani. “I think those will be really interesting avenues for us to go down in the future and we’re just starting to initiate conversations with other companies who might be good partners for us.”
You may be interested
Medical Cannabis Market | Global Trends, and Forecast to 2025Albert R - April 21, 2018
Increasing approval of medicinal cannabis products and growing research and development activities in the medical cannabis market are expected to support the growth of the market. For…
Familial Amyloid Cardiomyopathy Treatment Market-Moving Towards a Brighter FutureAlbert R - April 21, 2018
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy…
3D Cell Culture Market To Witness Robust Expansion by 2024Albert R - April 21, 2018
3D cell culture is group of biological cells that are allowed to grow in artificial media in all three dimensions. It is used in drug discovery and…